Skip to content

Clinical trial on Sleep problems

A prospective open label study to evaluate the safety, efficacy of KAL-HS-05 in the Management of Insomnia (Nidranasha) - NIL

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059312
Enrollment
30
Registered
2023-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G470- Insomnia

Interventions

None listed

Sponsors

Kerala Ayurveda Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Willing to give informed consent. 2. Healthy Indian male/ female volunteer aged between 18-65 years. 3. Must be able to adhere to the study visit schedule and other protocol requirements. 4. Willing to complete the questionnaires for the total duration of treatment. 5. Patients suffering from insomnia/loss of sleep from last 1 month. 6. Willing to avoid usage of any NSAIDs, Sleep inducing medication, etc. during the study duration. 7. Agree not to use any medication (prescription and over the counter), during the course of this study

Exclusion criteria

Exclusion criteria: 1. Patients on Psychiatry medicine. 2. Patients on hypnotic medicine or any other drugs known to cause drowsiness. 3. Pregnant or Breast feeding. 4. Inability to provide voluntary consent. 5. Patients with pre-existing severe systemic disease like uncontrolled diabetes, hypertension, and Cardiac illness etc necessitating long term medication. 6. Evidence of significant uncontrolled comorbid disease which in the investigators opinion would jeopardize patient participation. 7. Any clinically significant medical history, medical finding or an ongoing medical or psychiatric condition exists which in the opinion of the Investigator could jeopardize the safety of the subject, impact validity of the study results or interfere with the completion of study according to the protocol. 8. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ 9. Use of any anti-psychotic drugs for one week prior to Baseline. 10. Subjects who abuse drugs or alcohol drug screening not required. 11. Use of any investigational medication within 4 weeks prior to start of study drug. 12. Greater than moderate alcohol use

Design outcomes

Primary

MeasureTime frame
•% Improvement in sleep quality assessed by Sleep Quality scale[Time: Day 0 to Day 28]] •% Betterment in the anxiety and stress level assessed by Hamilton’s Anxiety assessment scale. [Time: Day 0 to Day 28] Timepoint: Day 0 and Day 28

Secondary

MeasureTime frame
Safety & vital signs Timepoint: Day 0 Day 7 Day 14 Day 21 & Day 28

Countries

India

Contacts

Public ContactJayashree M

Kerala Ayurveda Ltd.

sarala@keralaayurveda.biz9895517764

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026